Background: Previous studies have reported the effect of N-methylguanosine (mG) regulator methyltransferase like-1 protein (METTL1) in tumor initiation, metastasis, and chemosensitivity. However, the relationship between METTL1 and cancer immune infiltration is not validated and the prognostic significance of METTL1 in pan-cancer remains unclear.
Methods: Clinical parameters, including gender, age, lifetime, stage, and treatment response were analyzed to evaluate the prognostic significance of METTL1. To evaluate protein level of METTL1, the METTL1 activity was generated by single sample gene set enrichment analysis. The one-class logistic regression algorithm was used to calculate the stemness indices based on transcriptomics and methylation data of pan-cancer and pluripotent stem cells. The relationship between METTL1 expression or activity and tumor immune infiltration were analyzed to explore the significance of METTL1 in tumor immunotherapy. Meanwhile, the correlation between three immunotherapeutic biomarkers and METTL1 was investigated. Finally, to calculate the association between drug sensitivity and METTL1 expression, spearman correlation analysis was performed.
Results: METTL1 was not intimately related to gender, age, tumor stage, or treatment outcome of the various cancers, but it displayed potential prognostic significance for evaluating patient survival. High METTL1 expression was related to tumor progression-relevant pathways. Moreover, METTL1 exhibited a distinct correlation with tumor immune microenvironment infiltration and stemness indices. In the anti-PD-L1 cohort, patients in treatment response group exhibited significantly higher METTL1 expression than those in the no/limited response group. Further analysis showed that tumor cell lines with higher METTL1 expression were more sensitive to drugs targeting chromatin histone methylation, ERK-MAPK and WNT signaling pathways.
Conclusion: This study provides insight into the correlation of METTL1 with tumor immune infiltration and stemness in pan-cancer, revealing the significance of METTL1 for cancer progression and guiding more effective and generalized therapy strategies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008260 | PMC |
| http://dx.doi.org/10.3389/fimmu.2022.795240 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
METTL1 mediates PKM m7G modification to regulate CD155 expression and promote immune evasion in colorectal cancer.
J Transl Med
December 2024
Department of Cancer Diagnosis and Treatment Center, Affiliated Hospital of Jiangnan University, Wuxi, China.
Article Synopsis
- Colorectal cancer (CRC) shows resistance to immunotherapy, and m7G RNA modifications play a significant role in tumor growth and immune evasion.
- The study investigates how METTL1 influences m7G levels on PKM mRNA, leading to increased PKM2 protein expression and subsequent tumor progression through enhanced glycolysis and immune evasion mechanisms.
- Findings highlight METTL1 as a potential therapeutic target for CRC, suggesting that manipulating its signaling pathways could improve immunotherapy outcomes.
Aberrant METTL1-mediated tRNA mG modification alters B-cell responses in systemic autoimmunity in humans and mice.
Nat Commun
December 2024
Department of Rheumatology and Clinical Immunology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, China.
Upon activation, naive B cells exit their quiescent state and enter germinal center (GC) responses, a transition accompanied by increased protein synthesis. How protein translation efficiency is adequately adjusted to meet the increased demand requires further investigation. Here, we identify the methyltransferase METTL1 as a translational checkpoint during GC responses.
View Article and Find Full Text PDFA N7-methylguanosine modified circular RNA, circIPP2A2, promotes malignant behaviors in hepatocellular carcinoma by serving as a scaffold in modulating the Hornerin/PI3K/AKT/GSK3β axis.
Cell Death Dis
November 2024
Department of Hepatobiliary Surgery II, Zhujiang Hospital, Southern Medical University, 510000, Guangzhou, Guangdong, P. R. China.
Despite the advancements in treatment strategies, the long-term survival of hepatocellular carcinoma (HCC) is still pessimistic. Therefore, understanding the mechanisms of hepatocellular carcinoma may offer substantial benefits for patients. Our previous research has revealed that Hornerin promoted HCC progression by regulating the AKT signaling pathway.
View Article and Find Full Text PDFRNA methylation and breast cancer: insights into m6A, m7G and m5C.
Mol Biol Rep
November 2024
Department of breast surgery, The First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, China.
Article Synopsis
- - Breast cancer is the most common cancer diagnosed in women globally, characterized by its diverse molecular makeup and complex types, which pose challenges in treatment due to tumor heterogeneity and resistance.
- - Recent research has identified nearly 200 RNA modifications, with methylation playing a crucial role in cancer development, progression, and treatment resistance, particularly the N6-methyladenosine (m6A) modification, which involves key "writers," "readers," and "erasers."
- - The review discusses various RNA methylation types (m6A, m7G, m5C, m1A, and m3C), their effects on tumor behavior, and highlights their potential as therapeutic targets, suggesting they may enhance
RNA Methyltransferase NSUN5 Promotes Esophageal Cancer via 5-Methylcytosine Modification of METTL1.
Mol Carcinog
November 2024
Department of Clinical Laboratory, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, China.
Article Synopsis
- - Aberrant RNA modifications, particularly 5-methylcytosine (m5C), contribute to cancer progression, with the m5C methyltransferase NSUN5 being notably upregulated in esophageal cancer (ESCA) and showing potential for diagnostic use.
- - Silencing NSUN5 hampers ESCA cell growth and stalls the cell cycle, while increasing NSUN5 levels promotes tumor growth; experiments in mice further demonstrate that reduced NSUN5 leads to decreased tumor development.
- - NSUN5 enhances the expression of the oncogenic protein METTL1 by binding to its transcript, emphasizing the importance of the NSUN5/METTL1 pathway in ESCA and suggesting it as a possible target for cancer
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!